Pan Zhenhua (Jeff)


Beijing, China

Areas of Practice

Jeff focuses his practice primarily on corporate M&A, cross-border investment, private equity investment, corporate restructuring, investment disputes, and general corporate matters.

Jeff has advised dozens of well-known multinational enterprises, large state-owned enterprises, leading private enterprises and private equity funds as well as other clients on their investments in China and around the world spanning industrials including pharmaceuticals, food and consumer goods, new energy, machinery manufacturing, and household appliances. Jeff has accumulated rich experience in legal services and project management. He is especially good at handling large and complex domestic and overseas mergers and acquisitions by designing feasible transaction structures, solving thorny problems, and negotiating with different stakeholders. Focused on meeting clients’ needs, Jeff provides clients with practical solutions, efficient project management, and proper risk management plan to facilitate the successful completion of the transaction and realize clients’ goals.

Jeff is a partner in KWM’s Medicare Team, with particular expertise in investment and financing, acquisition, business cooperation, as well as regulatory and compliance issues concerning pharmaceutical businesses. He has counselled many well-known private equity funds and pharmaceutical companies on their financial investments, acquisition and exits with respect to different types of medical and pharmaceutical enterprises from start-ups, mature companies to listed companies. He has a deep understanding of the risks associated with enterprises at all stages. On the other hand, he has advised various medical enterprises on the introduction of financial investors, strategic sales and exit, design of equity incentive schemes, and corporate restructuring. He has also assisted clients in acquiring development and sales rights in both China and globe for different types of drugs and devices, including rare disease drugs, cancer drugs, cell therapy drugs, and gene sequencing and detection technologies, and carrying out strategic joint venture with partners.

Work experience

Mr. Pan joined King & Wood Mallesons in 2010. Prior to that, he worked in the Hong Kong and Beijing offices of a leading US law firm.

Mr. Pan is qualified to practice law in China and the State of New York.

His working languages are Chinese and English.

Current site :    CN   |   EN
China Hong Kong SAR
United States